Corbus Pharmaceuticals Reports $78.5 Million Net Loss and Advances Clinical Pipeline in 2025

Corbus Pharmaceuticals Holdings, Inc. reported significant financial developments in its recent 10-K filing for the fiscal year ending December 31, 2025. The company, which focuses on innovative therapies in oncology and obesity, recorded a net loss of approximately $78.5 million, an increase from a loss of $40.2 million in the previous year. This reflects a substantial rise in research and development expenses, which totaled $70.1 million, up 118% from $32.2 million in 2024. The increase was primarily driven by higher costs associated with the ongoing clinical trials for its lead product candidates, CRB-701 and CRB-913.

In terms of operational metrics, Corbus has made notable strides in its clinical pipeline. The company is advancing CRB-701, an antibody-drug conjugate targeting Nectin-4, through a Phase 1/2 clinical trial in the U.S. and Europe, with a Phase 3 trial ongoing in China. The company received fast track designation from the FDA for CRB-701 for specific cancer indications, which is expected to expedite its development process. Meanwhile, CRB-913, a cannabinoid receptor inverse agonist for obesity, has completed a Phase 1a study and is moving into a Phase 1b trial, indicating progress in its clinical development.

Corbus also reported a strong liquidity position, with cash, cash equivalents, and investments totaling approximately $163.3 million as of December 31, 2025. This financial cushion is expected to support the company's operations and clinical development activities for at least the next twelve months. The company raised approximately $70.2 million in net proceeds from a public offering completed in November 2025, which will further bolster its financial resources.

Looking ahead, Corbus anticipates continued operating losses as it invests heavily in the development of its product candidates. The company plans to seek additional funding through various means, including equity offerings and collaborations, to sustain its operations and clinical trials. The management remains optimistic about the potential of its drug candidates to address significant unmet medical needs in oncology and obesity, although the path to commercialization remains fraught with challenges, including regulatory approvals and market acceptance.